Antidepressant agents in short bowel syndrome

Area of Science:

• Pharmacology
• Gastroenterology
• Clinical Pharmacy

Background:

• Short bowel syndrome (SBS) significantly impacts nutrient and drug absorption.
• Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for mood disorders, often co-occurring with gastrointestinal conditions.

Purpose of the Study:

• To investigate the effect of a shortened small intestine on the concentrations of citalopram and escitalopram.
• To assess the relationship between small bowel length and antidepressant drug levels in patients with SBS.

Main Methods:

• Determined steady-state concentrations (Css) and concentration-dose ratios (CDRs) of citalopram/escitalopram.
• Analyzed data from patients receiving oral or intravenous administration of antidepressants.
• Correlated drug levels with remaining small bowel length and colonic involvement.

Main Results:

• High CDRs were observed in orally treated patients with >180 cm of small bowel.
• Elevated CDRs were also noted in patients with >80 cm of small bowel and 50% colonic length.
• Three patients exhibited low Css values, including one receiving intravenous treatment.

Conclusions:

• Variable drug absorption and metabolism in SBS patients complicate SSRI prescribing.
• Individualized dosing strategies are crucial for effective antidepressant therapy in this population.
• Further research is needed to optimize SSRI management in short bowel syndrome.